Fig. 4

Effect of baicalein treatment on NSCLC tumour growth in-vivo. A xenograft mouse model was generated using H-460 NSCLC cells. When tumour size reached approximately 50 mm³, animals were randomised into control and treatment groups (n = 7/group). Mice were administered either the flavanoid, baicalein (dissolved in 50 μl DMSO/PBS), or an equal volume of a vehicle control (20 % DMSO in PBS), by intra-tumoural injection (twice weekly). Baicalein treatment significantly reduced tumour growth, relative to vehicle-treated controls (a; n = 7/group, *p < 0.05). Treatment also prolonged survival of these xenograft mice (b). Immunohistochemical staining of the xenograft tumour tissue revealed reduced 12-LOX expression following baicalein treatment (c), while VEGF expression was also negatively affected (d)